## <u>Panel 2</u>: Academia, Government and Industry in Regulatory Science: Cross-Sector Collaboration and Managing Conflicts of Interest

## **Moderators**:

<u>Howard Bauchner, MD</u> - Editor-In-Chief of the Journal of the American Medical Association <u>Robert Califf, MD</u> - Former FDA Commissioner, Head of Health Policy and Strategy, Google Health and Verily Life Science (Alphabet)

## **Panelists:**

Mildred Cho, PhD - Professor of Pediatrics (Center for Biomedical Ethics) at Stanford Arthur Ciociola, PhD - Vice President, Head Regulatory Affairs, Global Drug Development Ophthalmology at Novartis

Malvina Eydelman, MD - Director, Office of Health Technology 1 at FDA

<u>Carol Linden, PhD</u> - Director of the Office of Regulatory Science and Innovation at FDA

<u>Andrew Weber, MS</u> - Accelerating Therapeutics for Opportunities in Medicine (ATOM), GlaxoSmithKline

- Are there effective models for cross sector collaborations among academics, industry and regulatory agencies?
- What are the biggest challenges for participants in cross-sector research collaborations in managing conflicts of interest?
- Does the openness required by academia and patient advocacy groups limit its opportunities for collaboration with government and industry?